Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aktis Oncology, Inc.AKTS · Entity 4711 | Chief Medical Officer | September 23, 2026 | September 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aktis Oncology, Inc.
Report date September 23, 2026 · Filed September 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-23 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-23 · Exercise / conversion · Acquired 12,500 · Balance 12,500 F1: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2026. Row 2 · 2026-09-23 · Sale · Disposed 5,099 · Balance 7,401 F1: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2026. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.6700 to $20.6500, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 3 · 2026-09-23 · Sale · Disposed 7,401 · Balance 0 F1: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2026. F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.6700 to $21.5000, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.95 · Expires 2034-06-30 | Direct | 208,718 |
Reported balance
After 2026-09-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-23 · Exercise / conversion · Disposed 12,500 · Balance 208,718 F1: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2026. F4: 25% of the original number of shares subject to the option vested on July 1, 2025, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2026.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.6700 to $20.6500, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.6700 to $21.5000, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: 25% of the original number of shares subject to the option vested on July 1, 2025, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 23, 2026 Filed Sep 24, 2026 20:05 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001193125-26-401014 · ownership.xml · derivative · entry 4 Czibere Akos · CIK 0002049427 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 208,718 Underlying: Common Stock · 12,500 shares Expires 2034-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2026. F4 · derivative.exercise_date: 25% of the original number of shares subject to the option vested on July 1, 2025, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive. Read SEC document |
| September 23, 2026 Filed Sep 24, 2026 20:05 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | SaleCommon Stock | 7,401 | $21.03 | $155,648.21 |
DisclosureSEC source: 0001193125-26-401014 · ownership.xml · nonDerivative · entry 3 Czibere Akos · CIK 0002049427 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2026. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.6700 to $21.5000, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 23, 2026 Filed Sep 24, 2026 20:05 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | SaleCommon Stock | 5,099 | $20.19 | $102,972.78 |
DisclosureSEC source: 0001193125-26-401014 · ownership.xml · nonDerivative · entry 2 Czibere Akos · CIK 0002049427 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,401 F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2026. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.6700 to $20.6500, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 23, 2026 Filed Sep 24, 2026 20:05 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | Exercise / conversionCommon Stock | 12,500 | $4.95 | $61,875.00 |
DisclosureSEC source: 0001193125-26-401014 · ownership.xml · nonDerivative · entry 1 Czibere Akos · CIK 0002049427 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2026. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 10:10 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001193125-26-300162 · ownership.xml · derivative · entry 5 Czibere Akos · CIK 0002049427 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,218 Underlying: Common Stock · 50,000 shares Expires 2034-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the original number of shares subject to the option vested on July 1, 2025, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 10:10 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | SaleCommon Stock | 4,371 | $28.71 | $125,481.79 |
DisclosureSEC source: 0001193125-26-300162 · ownership.xml · nonDerivative · entry 4 Czibere Akos · CIK 0002049427 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.6300 to $28.7400, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 10:10 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | SaleCommon Stock | 30,829 | $27.95 | $861,735.29 |
DisclosureSEC source: 0001193125-26-300162 · ownership.xml · nonDerivative · entry 3 Czibere Akos · CIK 0002049427 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,371 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.5300 to $28.5000, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 10:10 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | SaleCommon Stock | 14,800 | $27.13 | $401,484.04 |
DisclosureSEC source: 0001193125-26-300162 · ownership.xml · nonDerivative · entry 2 Czibere Akos · CIK 0002049427 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,200 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.5200 to $27.5100, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 10:10 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | Exercise / conversionCommon Stock | 50,000 | $4.95 | $247,500.00 |
DisclosureSEC source: 0001193125-26-300162 · ownership.xml · nonDerivative · entry 1 Czibere Akos · CIK 0002049427 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.